<DOC>
	<DOCNO>NCT00383747</DOCNO>
	<brief_summary>Patients schizophrenia variety cognitive deficit nicotine show normalize deficit . The purpose study investigate effect nicotine cognition schizophrenia.We evaluate effect transdermal nicotine compare placebo attentional impairment non-smokers schizophrenia control .</brief_summary>
	<brief_title>The Effects Nicotine Cognition Schizophrenia</brief_title>
	<detailed_description>We propose test efficacy safety transdermal nicotine attention work memory outpatient stable symptom schizophrenia treat high potency antipsychotic medication smoke cigarette use nicotine-containing product . This randomized , double-blind , placebo-controlled pilot study determine whether transdermal nicotine , initiate clinic set dose four hour safe effective improve attention spatial work memory deficit patient schizophrenia . This add-on study , subject continue usual medication treatment throughout . Subjects 30- non-smoking outpatient stable treat schizophrenia 30 normal control major mental illness match age sex parental education . Subjects randomize one 2 group order receive active placebo patch , use computer generate random number sequence . Randomization conceal use opaque envelope . Assessors subject blind group allocation . The primary outcome measure ' measure CPT-IP follow 4 hour administration transdermal nicotine patch . Secondary outcome measure performance task assess attention , numeric visuospatial work memory , psychomotor ability , executive function motivation reward follow nicotine patch administration . Specific Aims 1 . To evaluate effectiveness transdermal nicotine compare placebo attentional impairment patient schizophrenia Hypothesis 1.1 : Subjects demonstrate great signal detection measure ' ( hit vs. false alarm ) Continuous Performance Test Identical Pairs Version ( CPT-IP ) follow 4-hour nicotine administration compare placebo administration . Hypothesis 1.2 : Subjects demonstrate decrease false alarm CPT-IP follow 4-hour nicotine administration compare placebo administration . Hypothesis 1.3 : Subjects demonstrate decrease reaction time CPT-IP follow 4- hour nicotine administration compare placebo administration . 2 . To evaluate effect transdermal nicotine patient schizophrenia compare normal match control Hypothesis 2.1 : Schizophrenia subject demonstrate great improvement signal detection measure ' ( hit vs. false alarm ) Continuous Performance test identical pair version ( CPT-IP ) follow 4-hour nicotine administration compare normal control . Hypothesis 2.2 : Schizophrenia subject demonstrate great reduction false alarm CPT-IP follow 4-hour nicotine administration compare normal control . Hypothesis 2.3 : Schizophrenia subject demonstrate decrease reaction time CPT-IP follow 4- hour nicotine administration compare normal control . Performance Test Identical Pairs Version</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Patients : DSM IV diagnosis schizophrenia , age 18 60 inclusive , able provide inform consent , treat antipsychotic medication stable dose least 4 week , treat investigational medication past 30 day , WRAT3 IQ raw score great equal 35 , non smoker 3 months* , normal correct normal vision . Non Smoking define : 1 . Self report smoke single cigarette past 3 month . 2 . Salivary Cotinine level &lt; 30 ng/ml screen day test 3 . Expired air CO &lt; 9ppm day test Control Group : Age 18 60 inclusive , able provide inform consent , treat investigational medication past 30 day , WRAT3 IQ raw score great equal 35 , non smoker 3 months* , normal correct normal vision , Non Smoking define . Patients : Use nicotine contain product past 3 month self report , use cholinesterase inhibitor galantamine past 3 month , untreated ischaemic heart disease , uncontrolled hypertension , current unstable serious medical illness ( renal , neoplastic , hematological ) , allergy patch . Currently plan pregnant next 8 week , verify positive pregnancy test , childbearing potential use adequate contraception . Those childbearing potential include postmenopausal , surgically sterilize , male participant . Substance abuse past month : selfreported , diagnosed chart review , verify positive salivary test cotinine , cocaine , methamphetamine , amphetamine , ethanol , TCH , opiates PCP screen . Recent deterioration mental state , current major depressive disorder , history cognitive impairment secondary disorder head injury , dementia , general medical condition , diagnosis mental retardation Exclusion criterion : Controls : Past present DSM IV diagnosis schizophrenia , schizoaffective disorder , major depression , bipolar disorder , mental retardation . First degree relative diagnosis schizophrenia schizoaffective disorder , use cholinesterase inhibitor galantamine past 3 month , untreated ischaemic heart disease , uncontrolled hypertension , current unstable serious medical illness ( renal , neoplastic , hematological , ) allergy patch , currently plan pregnant next 8 week , verify positive pregnancy test , childbearing potential use adequate contraception . Those childbearing potential include postmenopausal , surgically sterilize , male participant . Substance abuse past month : selfreported , diagnosed chart review , verify positive salivary test cotinine , cocaine , methamphetamine , amphetamine , ethanol , TCH , opiates PCP screen . History cognitive impairment secondary disorder head injury , dementia , general medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>cognition</keyword>
	<keyword>nicotine</keyword>
	<keyword>schizophrenia</keyword>
</DOC>